Featured Publications

INOVIO is focused on developing and commercializing DNA medicines to help protect people from infectious diseases and help treat people with cancer and HPV-associated diseases. In the last several years INOVIO has had its data published in several prominent peer-reviewed medical journals including:

INO-4800 DNA vaccine induces neutralizing antibodies and T cell activity against global SARS-CoV-2 variants

npj Vaccines
October 2021

SARS-CoV-2 DNA Vaccine INO-4800 Induces Durable Immune Responses Capable of Being Boosted in a Phase 1 Open-Label Trial

The Journal of Infectious Diseases
January 2022

571. Safety and Immunogenicity of INO-4800, a COVID-19 DNA Vaccine as a Primary Series and Booster

Open Forum Infectious Diseases
December 2021

Immunogenicity of a DNA vaccine candidate for COVID-19

Nature Communications
May 2020

Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial

The Lancet Infectious Diseases
July 2019

Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial

The Lancet
September 2015

Filter by Category

HPV-Targeted

Immuno-Oncology (Non HPV-Associated)

Infectious Diseases (Non HPV-Associated)

Other Development Candidates

Delivery Technology/Proprietary Smart Device

COVID-19

dMAb™ (DNA-Encoded Monoclonal Antibodies)

HPV-Targeted

Title	Disease Target	Product
Immunotherapy Against HPV16/18 Generates Potent TH1 and Cytotoxic Cellular Immune Responses Science Translational Medicine — October 2012	Disease TargetCervical Dysplasia	ProductVGX-3100
Augmentation of cellular and humoral immune responses to HPV16 and HPV18 E6 and E7 antigens by VGX-3100 Molecular Therapy Oncolytics — January 2016	Disease TargetCervical Dysplasia	ProductVGX-3100
Clinical and Immunologic Biomarkers for Histologic Regression of High-Grade Cervical Dysplasia and Clearance of HPV16 and HPV18 after Immunotherapy Clinical Cancer Research — January 2018	Disease TargetCervical Dysplasia	ProductVGX-3100
Adverse obstetric outcomes after local treatment for cervical preinvasive and early invasive disease according to cone depth: systematic review and meta-analysis BMJ — July 2016	Disease TargetCervical Dysplasia	ProductVGX-3100
Immune Therapy Targeting E6/E7 Oncogenes of Human Papillomavirus Type 6 (HPV-6) Reduces or Eliminates the Need for Surgical Intervention in the Treatment of HPV-6 Associated Recurrent Respiratory Papillomatosis Vaccines — January 2020	Disease TargetRRP	ProductINO-3107
Immunotherapy Targeting HPV16/18 Generates Potent Immune Responses in HPV-Associated Head and Neck Cancer Clinical Cancer Research — January 2019	Disease TargetHead & Neck Cancer	ProductMEDI0457
Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial The Lancet — September 2015	Disease TargetCervical Dysplasia	ProductVGX-3100

Immuno-Oncology (Non HPV-Associated)

Title	Disease Target	Product
Synergy of Immune Checkpoint Blockade with a Novel Synthetic Consensus DNA Vaccine Targeting TERT Molecular Therapy — November 2017	Disease TargethTERT	ProductINO-5401
Highly Optimized DNA Vaccine Targeting Human Telomerase Reverse Transcriptase Stimulates Potent Antitumor Immunity Cancer Immunology Research — September 2013	Disease TargethTERT	ProductINO-5401
A Novel DNA Vaccine Platform Enhances Neo-antigen-like T Cell Responses against WT1 to Break Tolerance and Induce Anti-tumor Immunity Molecular Therapy — February 2017	Disease TargetWT1	ProductINO-5401
CD8+ T Cells Impact Rising PSA in Biochemically Relapsed Cancer Patients Using Immunotherapy Targeting Tumor-Associated Antigens Molecular Therapy — March 2020	Disease TargetPSA	ProductINO-5151
Co-delivery of PSA and PSMA DNA vaccines with electroporation induces potent immune responses Human Vaccines — January 2011	Disease TargetPSA, PSMA	ProductINO-5401

Infectious Diseases (Non HPV-Associated)

Title	Disease Target	Product
Synthetic Consensus HIV-1 DNA Induces Potent Cellular Immune Responses and Synthesis of Granzyme B, Perforin in HIV Infected Individuals Molecular Therapy — March 2015	Disease TargetHIV	ProductPENNVAX-GP
HIV-1 Env DNA Vaccine plus Protein Boost Delivered by EP Expands B- and T-Cell Responses and Neutralizing Phenotype In Vivo PLoS ONE — December 2013	Disease TargetHIV	ProductPENNVAX-GP
Immunogenicity of a novel engineered HIV-1 clade C synthetic consensus-based envelope DNA vaccine Vaccine — September 2011	Disease TargetHIV	ProductPENNVAX-GP
Intradermal SynCon® Ebola GP DNA Vaccine Is Temperature Stable and Safely Demonstrates Cellular and Humoral Immunogenicity Advantages in Healthy Volunteers The Journal of Infectious Diseases — March 2019	Disease TargetEbola	ProductINO-4201
Protective Efficacy and Long-Term Immunogenicity in Cynomolgus Macaques by Ebola Virus Glycoprotein Synthetic DNA Vaccines The Journal of Infectious Diseases — October 2018	Disease TargetEbola	ProductINO-4201
Rapid response to an emerging infectious disease – Lessons learned from development of a synthetic DNA vaccine targeting Zika virus Microbes and Infection — December 2018	Disease TargetZika	ProductINO-4600
Zika-Induced Male Infertility in Mice Is Potentially Reversible and Preventable by Deoxyribonucleic Acid Immunization The Journal of Infectious Diseases — July 2018	Disease TargetZika	ProductINO-4600
DNA vaccination protects mice against Zika virus-induced damage to the testes Nature Communications — June 2017	Disease TargetZika	ProductINO-4600
In vivo protection against ZIKV infection and pathogenesis through passive antibody transfer and active immunisation with a prMEnv DNA vaccine npj Vaccines — November 2016	Disease TargetZika	ProductINO-4600
A synthetic consensus anti–spike protein DNA vaccine induces protective immunity against Middle East respiratory syndrome coronavirus in nonhuman primates Science Translational Medicine — August 2015	Disease TargetMERS	ProductINO-4700
Broad cross-protective anti-hemagglutination responses elicited by influenza microconsensus DNA vaccine Vaccine — May 2018	Disease TargetInfluenza
An engineered bispecific DNA-encoded IgG antibody protects against Pseudomonas aeruginosa in a pneumonia challenge model Nature Communications — September 2017	Disease TargetPseudomonas
Rapid and Long-Term Immunity Elicited by DNA-Encoded Antibody Prophylaxis and DNA Vaccination Against Chikungunya Virus The Journal of Infectious Diseases — March 2016	Disease TargetChikungunya
Protection against dengue disease by synthetic nucleic acid antibody prophylaxis/immunotherapy Scientific Reports — July 2015	Disease TargetDengue
IFNL3-adjuvanted HCV DNA vaccine reduces regulatory T-cell frequency and increases virus-specific T-cell responses Journal of Hepatology — February 2020	Disease TargetHepatitis C	ProductGLS-6150
Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial The Lancet Infectious Diseases — July 2019	Disease TargetMERS	ProductINO-4700
Safety and Immunogenicity of an Anti–Zika Virus DNA Vaccine — Preliminary Report The New England Journal of Medicine — October 2017	Disease TargetZika	ProductINO-4600

Other Development Candidates

Title	Disease Target	Product
DNA-encoded bispecific T cell engagers and antibodies present long-term antitumor activity JCI Insight — April 2019	Disease TargetHER2

Delivery Technology/Proprietary Smart Device

Title	Disease Target	Product
A novel prototype device for electroporation-enhanced DNA vaccine delivery simultaneously to both skin and muscle Vaccine — September 2011	Disease TargetDelivery	ProductCELLECTRA
Integration of needle-free jet injection with advanced electroporation delivery enhances the magnitude, kinetics, and persistence of engineered DNA vaccine induced immune responses Vaccine — June 2019	Disease TargetDelivery	ProductCELLECTRA

COVID-19

Title	Disease Target	Product
Immunogenicity of a DNA vaccine candidate for COVID-19 Nature Communications — May 2020	Disease TargetCOVID-19	ProductINO-4800
571. Safety and Immunogenicity of INO-4800, a COVID-19 DNA Vaccine as a Primary Series and Booster Open Forum Infectious Diseases — December 2021	Disease TargetCOVID-19	ProductINO-4800
SARS-CoV-2 DNA Vaccine INO-4800 Induces Durable Immune Responses Capable of Being Boosted in a Phase 1 Open-Label Trial The Journal of Infectious Diseases — January 2022	Disease TargetCOVID-19	ProductINO-4800
INO-4800 DNA vaccine induces neutralizing antibodies and T cell activity against global SARS-CoV-2 variants npj Vaccines — October 2021	Disease TargetCOVID-19	ProductINO-4800

dMAb™ (DNA-Encoded Monoclonal Antibodies)

Title	Disease Target	Product
Synthetic nucleic acid antibody prophylaxis confers rapid and durable protective immunity against Zika virus challenge Human Vaccines & Immunotherapeutics — December 2019	Disease TargetZika	ProductINO-A002
In Vivo Delivery of a DNA-Encoded Monoclonal Antibody Protects Non-human Primates against Zika Virus Molecular Therapy — April 2019	Disease TargetZika	ProductINO-A002
In Vivo Delivery of Synthetic Human DNA-Encoded Monoclonal Antibodies Protect against Ebolavirus Infection in a Mouse Model Cell Reports — November 2018	Disease TargetEbola
Synthetic DNA-Encoded Monoclonal Antibody Delivery of Anti–CTLA-4 Antibodies Induces Tumor Shrinkage In Vivo Cancer Research — November 2018	Disease TargetCTLA-4
Novel prostate cancer immunotherapy with a DNA-encoded anti-prostate-specific membrane antigen monoclonal antibody Cancer Immunology, Immunotherapy — August 2017	Disease TargetProstate Cancer
DMAb inoculation of synthetic cross reactive antibodies protects against lethal influenza A and B infections npj Vaccines — July 2017	Disease TargetInfluenza

© Copyright 2023 INOVIO Pharmaceuticals. All rights reserved.